Studies to understand mechanisms by which PRMT5 overexpression may cooperate with recurrent genomic lesions to contribute to CLL pathogenesis and progression are also necessary as the critical targets for response to PRMT5 inhibition are likely context-dependent for each cancer type54. This evidence concerns the gene PRMT5 and B-cell chronic lymphocytic leukemia.